Abstract: The present disclosure pertains to a construction consisting of in the order from the outside towards the inside: an occlusive or non-occlusive backing substrate; a drug-loaded layer including a therapeutic concentration of at least one or a combination of cosmetic and/or pharmaceutical active ingredients; a permeable or semi-permeable support substrate; a non-drug loaded cured silicone gel adhesive layer cured onto the permeable or semi-permeable support substrate; and a temporary release liner configured to protect the cured silicone gel adhesive layer.

Abstract: The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at least one agent that provides occlusivity when the formulation is applied onto a patient's skin. The at least one active may be a healthcare and/or pharmaceutical active.

Abstract: The present disclosure relates to compositions comprising: i) an aqueous silicone emulsion comprising; A) 0.5 wt % to 95 wt % of a silicone gum, resin, or PSA, B) 0.1 to 90 wt % of an ethylene oxide/propylene oxide block copolymer, and sufficient amount of water to sum all ingredients of the silicone gum emulsion to 100 weight percent, ii) a healthcare active, and iii) an optional enhancer(s).

Abstract: The present invention is drawn to formulations and related methods for treating dermatitis or psoriasis. The formulation can include triamcinolone acetonide, a polymer selected from the group of a poly(2-hydroxyalkylacrylate), a poly(2-hydroxyalkylmethacrylate), and combinations thereof. The formulation also includes a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent.

Abstract: The present disclosure relates to biodegradable intravaginal rings for the delivery of therapeutic or prophylactic agent, inter alia, antiviral agents. The present disclosure further relates to biodegradable polyurethanes which will allow therapeutic/prophylactic agents to be released in a controlled manner that will not degrade when in use, but will degrade upon disposal.

Abstract: The present disclosure relates to biodegradable intravaginal rings for the delivery of therapeutic or prophylactic agent, inter alia, antiviral agents. The present disclosure further relates to biodegradable polyurethanes which will allow therapeutic/prophylactic agents to be released in a controlled manner that will not degrade when in use, but will degrade upon disposal.

Abstract: The present invention is drawn to systems, methods, and formulations for treating nail disorders. The system comprises an active agent formulation and a first barrier film. The active agent formulation includes an active agent and an aqueous liquid component. The first barrier film is configured to form a sheath over at least a portion of a finger or toe on which the nail is located. An optional second barrier film, with lower moisture vapor transmission rate than the first barrier film, is placed between the first barrier film and the active agent formulation (or between the active agent formulation and the external environment) to reduce the water evaporation from the active agent formulation. The sheath is configured to be capable of securing and retaining the active agent formulation within the sheath on a finger nail or toe nail while reducing evaporation of the liquid component of the aqueous liquid component of the active agent formulation.